For Research Use Only — Not for human or veterinary use.

Education

NAD+ in Longevity Research: Coenzyme Function and Cellular Energy Metabolism

A research overview of NAD+ as a redox coenzyme and sirtuin cofactor, its age-related decline, and the pharmacokinetic and mitochondrial-function research domains it has been studied in.

NAD+
All content on this page is for laboratory and academic reference only. This compound is supplied under a Research Use Only framework for in vitro and preclinical investigation by qualified personnel. Nothing on this page is clinical guidance, and it should not be interpreted as instructions for use in humans or animals.

Key Takeaways

  • NAD+ is a coenzyme central to cellular redox reactions and energy metabolism, and also serves as an essential cofactor for non-redox enzymes including sirtuins.[1]
  • Sirtuins couple NAD+ breakdown to protein deacylation, a mechanistic link researchers propose connects energy metabolism regulation to aging and longevity control.[2]
  • Tissue and cellular NAD+ levels are reported to decline with age across multiple model organisms, including rodents and humans.[1]
  • A pilot pharmacokinetic study of intravenous NAD+ infusion in humans found NAD+ was rapidly cleared from plasma within the first two hours, with metabolite profiles consistent with specific NAD+-metabolizing enzyme activity.[3]
  • Separately, oral NAD+ precursor compounds (such as nicotinamide riboside) have been studied for their ability to raise blood NAD+ levels — a mechanistically distinct research approach from direct NAD+ administration.[4]

What It Is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, central to the redox reactions that drive cellular energy metabolism. Beyond its redox role, NAD+ also functions as an essential cofactor for a set of non-redox enzymes, including sirtuins, CD38, and poly(ADP-ribose) polymerases (PARPs) — enzyme families studied extensively in aging and cellular-stress research.[1]

Mechanism & Pathway

The mechanism most associated with NAD+ in longevity research runs through sirtuins, a family of proteins that couple NAD+ breakdown to protein deacylation (the removal of chemical groups from proteins that regulate their activity). This coupling is proposed as the mechanistic bridge that translates cellular energy metabolism into downstream effects on aging and longevity pathways studied across model organisms.[2] Because NAD+ has limited direct cell permeability, pharmacokinetic research distinguishes between two study approaches: direct NAD+ administration, and oral supplementation with NAD+ precursor molecules such as nicotinamide riboside (NR), which are separately metabolized into NAD+ within cells. A pilot study of intravenous NAD+ infusion in humans found the compound was rapidly cleared from plasma within the first two hours post-infusion, with urinary metabolite patterns consistent with specific NAD+-processing enzyme activity.[3]

Research Domains

  • Aging & longevity research — reviews describe tissue and cellular NAD+ decline across multiple model organisms with age, alongside proposed sirtuin-mediated mechanisms linking this decline to age-related functional changes.[1][2]
  • Human pharmacokinetics research — a pilot study measuring plasma and urine NAD+ metabolome changes during a controlled intravenous infusion characterized clearance and metabolite patterns in human subjects.[3]
  • Oral precursor supplementation research — separate human trials of NAD+ precursor compounds (e.g. nicotinamide riboside) report measurable increases in blood NAD+ levels following oral dosing.[4]
  • Mitochondrial function research — NAD+'s central role in redox metabolism places it in mitochondrial-function research models studying cellular energy production and metabolic homeostasis.

Comparative Notes

NAD+ is mechanistically distinct from the peptide compounds elsewhere in this catalog — it is a small-molecule coenzyme rather than an amino-acid chain, and its research basis centers on redox chemistry and sirtuin cofactor activity rather than receptor binding. Within its own research literature, an important distinction is direct NAD+ administration versus precursor supplementation (NR, NMN): the two are studied as pharmacokinetically distinct approaches to raising cellular NAD+ availability.

NAD+ product page →

Certificate of Analysis: What to Look For

A Certificate of Analysis for an NAD+ research vial should report, at minimum: confirmed compound identity and net content (typically via mass spectrometry or HPLC-based methods appropriate to a small-molecule coenzyme rather than a peptide sequence). Vials should be stored lyophilized at -20°C, protected from light, consistent with handling guidance for the other lyophilized compounds in this catalog.

References

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. PMID: 33353981
  2. Imai SI, Guarente L (2016). It takes two to tango: NAD+ and sirtuins in aging/longevity control. NPJ Aging Mech Dis. PMID: 28721271
  3. Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. PMID: 31572171
  4. Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD (2017). An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. PMID: 29211728

FAQ

NAD+ is a coenzyme central to cellular redox reactions and energy metabolism, and also serves as a cofactor for non-redox enzymes including sirtuins.[1]

NAD+ levels are reported to decline with age, and sirtuins couple NAD+ breakdown to protein deacylation — a mechanism proposed to link energy metabolism to aging and longevity pathways.[1][2]

A pilot intravenous infusion study found NAD+ was rapidly cleared from plasma within the first two hours, with metabolite patterns consistent with specific NAD+-processing enzyme activity.[3]

NAD+ itself has limited direct cell permeability, so a separate line of research studies oral precursor compounds that are metabolized into NAD+ within cells — pharmacokinetically distinct from direct NAD+ administration.[4]

A COA for an NAD+ research vial should report confirmed compound identity and net content, using analytical methods appropriate to a small-molecule coenzyme.

No. NAD+ is supplied strictly under a Research Use Only framework for laboratory and preclinical investigation, and none of the studies referenced here involve clinical administration guidance outside their own regulated trial or pilot-study protocols.

Related Guides